Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, Long JE, Hamilton P, McNutt A, Kasman I, Nannini MA, Reslan HB, Cao TC, Ho CC, Barck KH, Carano RA, Foreman O, Eastham-Anderson J, Jubb AM, Ferrara N, Johnson L, Anti-VEGF antibody therapy does not promote metastas...
Fig. 7: Anti-tumor effects of the KRAS(G12D) inhibitors alone and in combination with anti-PD-L1 antibody. a Nude mice injected with Panc 04.03 cells at Day 0 were later intraperitoneally injected with TH-Z827 (at 10 mg/kg or 30 mg/kg) according to the indicated dosage schedule...
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune... SPG decreased tumor growth in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models.The combination therapy changed the immune microenvironment of PC...
G12D, and Pan-Keratin in primary epithelial cells, SV40T immortalized cells, and SV40T immortalized cells transformed with KRASG12D (SV40T LV-GK; two lines, CL1 and CL2) Samples are from the same gel/blot with different IR Dye exposures depending on the secondary for the primary antibody...
the KRAS G12D program, the company has several molecules in development, including TSN084, a Type II multi-kinase inhibitor; TSN222, a first in kind dual acting tumor immune agonist (DATIA®), and a platform...
Finally, inhibition of SCF using a neutralizing antibody significantly attenuated Snail-induced migration of mast cells. Together, these results elucidate how the EMT regulator Snail contributes to inflammation associated with PDAC tumors. ©2014 American Association for Cancer Research....
the KRAS G12D program, the company has several molecules in development, including TSN084, a Type II multi-kinase inhibitor; TSN222, a first in kind dual acting tumor immune agonist (DATIA®), and a platform for antibody drug conjugates (ADCs) featuring proprietary linkers and novel ...
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced sol... We completed a phase I clinical trial to test the safety and toxicity of combined treatment with cixutumumab (anti-IGF-1R antibody...
Correction to: AntiPD1 antibodyactivated Th17 cells subvert reinvigoration of antitumor cytotoxic Tlymphocytes via myeloid cellderived COX2/PGE2 Anti-PD-1 antibody-mediated activation of type 17T-cells undermines checkpoint inhibitor therapy in the LSL-KrasG12Dmurine lung cancer model. Herein, we es...
Immunolocalization by an anti-pan-Ras antibody (F, G) and an Alexa514-conjugated secondary antibody giving a green signal (C, D, F, G,), direct visualization of the cyan signal pseudocolored in red (B, D, E, G) and direct visualization of the signal displayed by the nuclear dye 7-...